Heiner H Wedemeyer: Influence Statistics

Heiner H Wedemeyer

Heiner H Wedemeyer

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany | Department of Gastroenterology, ...

Heiner H Wedemeyer: Expert Impact

Concepts for which Heiner H Wedemeyer has direct influence: Chronic hepatitis , Hepatitis virus , Hepatitis delta , Liver cirrhosis , Hcv rna , Acute hepatitis , Liver transplantation .

Heiner H Wedemeyer: KOL impact

Concepts related to the work of other authors for which for which Heiner H Wedemeyer has influence: Chronic hepatitis , Hepatocellular carcinoma , Hcv infection , Liver disease , Nk cells , Antiviral therapy , Hbv dna .

KOL Resume for Heiner H Wedemeyer

Year
2022

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany

Hannover Medical School (MHH)

2021

Department of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany;, (L.E.B.-M.);, (J.D.);, (F.N.);, (L.S.);, (M.L.);, (M.P.M.);, (H.W.);, (E.J.)

Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany

Hannover Medical School: Medizinische Hochschule Hannover

Prominent publications by Heiner H Wedemeyer

KOL-Index: 24011 . BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone. METHODS: We conducted a randomized ...
Known for Hdv Rna | Adefovir Peginterferon | Hepatitis Delta | 48 Weeks
KOL-Index: 20701 . BACKGROUND: Direct-acting antivirals for chronic hepatitis C (HCV) infection have reduced the need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost implications of using HCV core antigen testing to replace HCV RNA testing for confirmation of diagnosis, on-treatment monitoring, and determination of sustained virological response (SVR). METHODS: In a retrospective ...
Known for Hcv Rna | Core Antigen | Acting Antivirals | 12 Weeks
KOL-Index: 17133 . CONTEXT: Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death. OBJECTIVE: To assess the association between sustained virological response (SVR) and all-cause mortality in patients with chronic HCV infection and advanced hepatic fibrosis. DESIGN, SETTING, AND PATIENTS: An international, multicenter, long-term ...
Known for Advanced Hepatic Fibrosis | Virological Response | 95 Svr | Chronic Hepatitis
KOL-Index: 16519 . BACKGROUND & AIMS: Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Although HDV-associated liver disease is considered immune-mediated, adaptive immune responses against HDV are weak. Thus, the role of several other cell-mediated mechanisms such as those driven by mucosa-associated invariant T (MAIT) cells, a group of innate-like T cells highly enriched in ...
Known for Mait Cells | Chronic Hepatitis | Delta Virus | Hdv Infection
KOL-Index: 16415 . BACKGROUND: Hepatitis B surface antigen (HBsAg) clearance during chronic hepatitis B (CHB) infection is associated with improved long-term clinical outcome, so is considered an important therapeutic goal in CHB. Studies have shown that serum HBsAg quantification during, and at end of, treatment may predict long-term HBsAg loss. OBJECTIVES: Performance comparison of the qualitative Elecsys ...
Known for Elecsys Hbsag | Architect Assay | Antigens Hepatitis | Hbv Genotype
KOL-Index: 16225 . BACKGROUND: The elimination of hepatitis B virus surface antigen (HBsAg) is the final goal of hepatitis B treatment, but is rarely achieved. As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring. METHODS: Within this study, 23 liver ...
Known for Hbv Dna | Surface Antigen | Hbsag Hbeag | Hepatitis Virus
KOL-Index: 16168 . BACKGROUND & AIMS: Treatment with nucleos(t)ide analogues (NA) leads to hepatitis B virus (HBV) DNA suppression in most patients with chronic hepatitis B (CHB), but HBV surface antigen (HBsAg) loss rates are low. Upon NA discontinuation, HBV DNA can return rapidly with ensuing alanine aminotransferase flares and induction of cytokines. Several studies reported higher HBsAg loss rates after ...
Known for Cell Responses | Chronic Hepatitis | Discontinuation Therapy | Hbsag Loss
KOL-Index: 16097 . BACKGROUND & AIMS: The European Association for the Study of the Liver (EASL) guidelines recommend HCV RNA measurements at specific time points during sofosbuvir(SOF)-therapy. However, it remains unclear, how these results should be interpreted. We aimed to analyze whether on-treatment HCV RNA levels predict relapse comparing the CobasAmpliPrep/CobasTaqMan v2.0 (CAP/CTM) and Abbott ...
Known for Hcv Rna | Art Patients | Cap Ctm | Antiviral Therapy
KOL-Index: 14981 . BACKGROUND & AIMS: The quantifiable level of HBsAg has been suggested as a predictor of treatment response in chronic hepatitis B. However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients. METHODS: 226 HBV-monoinfected ...
Known for Hbsag Hbv | Acute Hepatitis | Antiviral Therapy | Studies Dna
KOL-Index: 14518 . BACKGROUND: Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ...
Known for Sustained Virologic Response | 12 Weeks Treatment | Abt450 Ombitasvir | Patients Cirrhosis
KOL-Index: 14312 . BACKGROUND AND AIMS: Novel, potent, and well-tolerated hepatitis C virus (HCV) drugs are needed. BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro. Preclinical toxicology data and studies in healthy volunteers supported the administration of BILN 2061 to patients with HCV infection. METHODS: The antiviral efficacy, pharmacokinetics, and tolerability of 25, 200, ...
Known for Biln 2061 | Antiviral Efficacy | Genotype 1 | Protease Inhibitor
KOL-Index: 14293 . Different viral dominance patterns have been documented in coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) based on HBV DNA and HCV RNA quantification. In most cases, HCV is dominant and suppresses HBV replication. In vitro studies revealed that there is most probably no direct interference between HBV and HCV replication. We hypothesized that indirect mechanisms ...
Known for Hbv Hcv | Hepatitis Virus | Coinfected Patients | Surface Antigen
KOL-Index: 14023 . BACKGROUND: Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population. METHODS: We studied all HBV monoinfected patients treated with ETV from 11 European referral centres within the VIRGIL Network. RESULTS: A total of ...
Known for Risk Scores | Hepatocellular Carcinoma | Entecavir Treatment | Chronic Hepatitis
KOL-Index: 13800 . Recent studies suggest that diabetes mellitus increases the risk of developing hepatocellular carcinoma (HCC). The aim of this study is to quantify the risk of HCC among patients with both diabetes mellitus and hepatitis C in a large cohort of patients with chronic hepatitis C and advanced fibrosis. We included 541 patients of whom 85 (16%) had diabetes mellitus. The median age at ...
Known for Diabetes Mellitus | Hcc Patients | Hepatocellular Carcinoma | Hepatitis Cirrhosis

Key People For Chronic Hepatitis

Top KOLs in the world
#1
Patrick Marcellin
chronic hepatitis adefovir dipivoxil hcv genotype
#2
Michael Peter Manns
chronic hepatitis liver transplantation hepatocellular carcinoma
#3
Anna Shuk‐Fong Lok
chronic hepatitis hepatocellular carcinoma united states
#4
Stefan S Zeuzem
chronic hepatitis hcv genotype liver fibrosis
#5
Jay H Hoofnagle¶¶
chronic hepatitis liver injury united states
#6
Zachary D Goodman
chronic hepatitis liver fibrosis hepatocellular carcinoma

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany | Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany;, wed